CJC-1295 isn't available on pharmacy shelves in Dealu or anywhere else for that matter — it's a research compound supplied via a dedicated online market. What this means for Dealu researchers is that your location matters far less than your ability to verify analytical documentation — and those verification methods are available to every researcher. What consistently distinguishes top CJC-1295 vendors is complete batch-specific analytical documentation: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for contamination assurance. The sections below cover what Dealu researchers need to know about finding, evaluating, and storing CJC-1295 for scientific research use.
CJC-1295 Mechanisms Explained
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Dealu researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Evaluate CJC-1295 Vendors
The first step for any Dealu researcher sourcing CJC-1295 is locating suppliers that experienced researchers actively recommend — search results alone are too heavily influenced by marketing spend. The HPLC purity trace is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with small or absent impurity peaks representing impurities — purity should be stated as ≥98%. The combination of peer feedback and direct document verification is the most reliable sourcing approach — community feedback surfaces patterns individual COA review misses, and vice versa. Hold lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order CJC-1295 — ships to Dealu
COA-verified · International tracking · Research grade
All use of CJC-1295 in Dealu or anywhere is research use only — this compound is not approved for therapeutic human application, and all handling should follow research laboratory protocols. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. Endotoxin testing in the CJC-1295 COA is non-negotiable — gram-negative bacterial endotoxins can trigger severe inflammatory responses at trace quantities, and no cost saving makes omitting this acceptable. Researchers combining CJC-1295 with other compounds should review the available literature for documented interactions before running stacked compound experiments.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
